Episodes

AbbVie's Etentamig Clears Phase 3 Myeloma Trial on Both Endpoints & GSK Pays HUTCHMED $110M Upfront for KRAS-EGFR Drug Fri, Sep 4, 2026
uniQure Files Huntington's Gene Therapy — FDA Reversed Twice Already Thu, Sep 3, 2026
Alumis TYK2 Pill Fails Lupus: What's Left of the Platform & Kazia's PI3K Inhibitor Cuts CRC Tumor Burden 52% Wed, Sep 2, 2026
Novartis, BMS Halt Autoimmune CAR-T Trials on Safety & FDA Clears Takeda's Mimrylo in Polycythemia Vera Tue, Sep 1, 2026
AstraZeneca's Wainua Missed in ATTR-CM: The Stabilizer Problem Mon, Aug 31, 2026
Cytokinetics Wins Non-Obstructive HCM, Stock Falls Anyway & Teva bids $57.5M for BioXcel asset as shares collapse 66% Sat, Aug 29, 2026
Roivant's JAK1/TYK2 Pill Wins First Dermatomyositis Nod & Spyre Deprioritizes TL1A Drug After RA Miss Fri, Aug 28, 2026
Revolution Medicines' RAS Inhibitor Cleared in Five Weeks & Spyre's TL1A Antibody Misses in Rheumatoid Arthritis Thu, Aug 27, 2026
Jazz’s HER2 Bispecific Wins First-Line Gastric & McKesson Pays $2.25B for Precision Medicine Wed, Aug 26, 2026
Regenxbio Plunges 26% as FDA Halts Hunter Gene Therapy & Capricor Duchenne Decision Slips to Nov. 22 on Narrower Label Mon, Aug 24, 2026
AstraZeneca Kills Volrustomig Lung Trial, Discloses No Data Sun, Aug 23, 2026
Akeso's Third ADC: What "Differentiated" Still Has to Prove & Leads Biolabs Puts 4-1BB Back on the Board Sat, Aug 22, 2026
Moderna and Merck's mRNA Cancer Vaccine Wins Phase 3 — But There's No Filing Date Fri, Aug 21, 2026
Heidi Overton FDA Pick: What It Means for Approvals Thu, Aug 20, 2026
Amylyx Avexitide Wins Phase 3: 55% Fewer Hypoglycemic Events, Filing at Stake Wed, Aug 19, 2026
EyePoint Crashes 67% After Duravyu Fails Phase 3 in Wet AMD Tue, Aug 18, 2026
Lilly's Retatrutide Lawsuits: Enforcing a Drug Nobody Has Approved Mon, Aug 17, 2026
Zenbexus Approval Tests a New Endpoint: What BMS Still Owes the FDA Fri, Aug 14, 2026
Taiho and Cullinan Stop Lung Cancer Trial Early — Data Too Good to Stay Blinded Thu, Aug 13, 2026
Definium's LSD Pill Wins Phase 3 in Anxiety — What It Means for Psychiatry Thu, Aug 13, 2026
WuXi AppTec Wins Injunction: Pentagon's Military Label Halted for Now Wed, Aug 12, 2026
Jazz Buys Actio Biosciences in $1.3B Rare Epilepsy Deal Mon, Aug 10, 2026
Takeda's Orzeyful Approval Opens the Orexin Market — and a Payer Fight Sun, Aug 9, 2026
Vedanta's $60M Lifeline: What VE303 Must Prove in C. diff Phase 3 Sat, Aug 8, 2026
Replimune Wins FDA Approval for Melanoma Drug After Two Rejections Fri, Aug 7, 2026
Merck's 2028 Keytruda Cliff: The Oral PCSK9 Bet Wed, Aug 5, 2026
Curium Buys Lantheus for Up to $8B in Cash-and-CVR Deal Mon, Aug 3, 2026
AstraZeneca, Bristol Myers Squibb Weigh a $400B Merger Mon, Aug 3, 2026
Novo Nordisk's ZEUS Failure: The Inflammation Thesis Just Got Repriced Sat, Aug 1, 2026
Replimune Wins 10-3 FDA Panel Vote for Melanoma Drug RP1 Fri, Jul 31, 2026
Capricor's Duchenne Cell Therapy Voted Down — What It Means for the Field Thu, Jul 30, 2026
Replimune RP1 on the Brink: FDA Calls Melanoma Data Uninterpretable Wed, Jul 29, 2026
Capricor Craters 67% as FDA Questions Deramiocel Data Tue, Jul 28, 2026
Amgen Refuses to Pull Tavneos: FDA Showdown Lands Wednesday Sun, Jul 26, 2026
Novo Seeks Injunction on Lilly Obesity Ads: The Comparative Claims Precedent Sat, Jul 25, 2026
J&J Bispecific Combo Cuts Myeloma Progression Risk 89% Fri, Jul 24, 2026
GSK Wins First Lung Cancer Approval — Jideytro Validates a $10.6B Bet Thu, Jul 23, 2026
Novo Sues Lilly Over GLP-1 Ads: The Dose-Comparison Fight That Could Rewrite Obesity Marketing Wed, Jul 22, 2026
Tempus AI Buys Personalis for $1.5B in MRD Cancer Push Tue, Jul 21, 2026
GSK Kills Camlipixant: The P2X3 Cough Bet Just Went to Zero Sun, Jul 19, 2026
GSK Kills Camlipixant: The $2B Bellus Bet Unravels Sat, Jul 18, 2026
Merck's Sac-TMT Beats Chemo in Lung Cancer — Keytruda's Cliff Answer Thu, Jul 16, 2026
Celcuity Revtorpyk Approved: The Label Line That Makes It a Takeout Target Wed, Jul 15, 2026
GSK to File Jemperli in Rectal Cancer After Phase 2 Win Tue, Jul 14, 2026
AstraZeneca's Wainua Stumbles: The Clinic Pushed Back on Pharma's Deal Boom Mon, Jul 13, 2026
GSK Ends Alector Neuroscience Bet: What the $2.2B Unwind Signals Sat, Jul 11, 2026
Wainua Fails Pivotal ATTR-CM Trial; Ionis Sinks 20% Fri, Jul 10, 2026
FDA Halts Drug Rejection Letters — What It Means for Competitive Intel Thu, Jul 9, 2026
Vera's TRUTAKNA Wins FDA Nod: The eGFR Readout That Decides the IgAN Race Wed, Jul 8, 2026
Vertex Buys Crinetics for $10B in Endocrinology Push Tue, Jul 7, 2026
Enbrel Price Cap Blocked: One Ruling That Could Reshape States Drug Pricing Sat, Jul 4, 2026
Roche Divarasib Beats Both KRAS G12C Rivals in Phase 3 Lung Cancer Study Sat, Jul 4, 2026
Tregzi Approved — Orca Bio Opens a New Lane in Cell Therapy Thu, Jul 2, 2026
NEJM Retracts Tavneos Pivotal Trial; Ionis Tryngolza PDUFA Today Wed, Jul 1, 2026
FDA Approves Viridian for Thyroid Eye Disease; Merck KGaA's $11.3B Bio-Techne Deal Sat, Jun 27, 2026
Ionis Tryngolza FDA Label Expansion Hits Commercial Inflection Fri, Jun 26, 2026
FDA Approves Gilead's Trodelvy for Front-Line TNBC; Lilly's $1.9B Abbisko Deal Thu, Jun 25, 2026
Pfizer Seagen ADC Fails in Lung Cancer Phase 3; CMS Settles Opzelura Classification Wed, Jun 24, 2026
AbbVie's $10.9B Apogee Buy Targets Dupixent; 1st Solid Tumor CAR-T Approved in China Tue, Jun 23, 2026
US Probes Germany Drug Pricing; Moderna Flu Vaccine Wins Unanimous FDA Panel Sat, Jun 20, 2026
Moderna mFlusiva Wins Unanimous VRBPAC Vote; NovoCure TRIDENT Fails in GBM Fri, Jun 19, 2026
UniQure AMT-130 Surges 70% on FDA Reversal; Jazz-AbCellera $4.1B TCE Deal Thu, Jun 18, 2026
BridgeBio BBP-418 Sweeps LGMD Phase 3; FDA Scrutinizes Moderna Flu Vaccine Wed, Jun 17, 2026
CMS Targets SubQ Keytruda and Opdivo Loophole; Takeda Beats Sotyktu Head-to-Head Tue, Jun 16, 2026
EHA 2026 Special — Full Meeting Recap Mon, Jun 15, 2026
FDA Approves Merck Welireg-Keytruda for Kidney Cancer; Jazz Zepzelca Phase 3 Fails Sat, Jun 13, 2026
Takeda Zasocitinib Beats Sotyktu in Head-to-Head Phase 3; Summit Pulls $500M Offering Fri, Jun 12, 2026
Parabilis Sets Record $670M Biotech IPO; Sanofi Halts Riliprubart Phase 3 Thu, Jun 11, 2026
ADA 2026 Special: The full recap Thu, Jun 11, 2026
The Pharma Closeout Special Report Mon, Jun 8, 2026
Alnylam's $2B AI-RNA Deal with Inceptive; Lundbeck Bocunebart Migraine Data Mon, Jun 8, 2026
SCOTUS Backs Hikma Skinny-Label Win on Vascepa; ADC Therapeutics Crashes 50% on Death Fri, Jun 5, 2026
ASCO 2026 Special, Part 2 — ThClosing Days: Iza-bren Doubles Down in TNBC & Esophageal Wed, Jun 3, 2026
ASCO 2026 Special — Comprehensive Opening Weekend: Daraxonrasib Doubles Pancreatic OS Mon, Jun 1, 2026
ASCO 2026: Revolution Medicines Pancreatic Data Called 'Unprecedented'; Ivonescimab 34% OS Mon, Jun 1, 2026
Pfizer's $10.5B Innovent Deal Extends China Licensing Wave; BMS Mezigdomide Phase 3 Sat, May 30, 2026
GSK/Ionis Bepirovirsen Achieves 19% Functional Cure in Hepatitis B Fri, May 29, 2026
Pfizer's Next-Gen Pneumonia Vaccine Beats Prevnar 20; BMS Deploys Anthropic AI Thu, May 21, 2026
Takeda $885M Antitrust Verdict; Bimzelx Beats Skyrizi in PsA Head-to-Head Thu, May 21, 2026
Regeneron LAG-3 Phase 3 Failure Crashes Stock 11%; Supreme Court Cements IRA Tue, May 19, 2026
FDA's CDER Chief Høeg Expected to Exit; Tecentriq Wins Bladder Cancer Approval Sun, May 17, 2026
AstraZeneca Imfinzi Phase 3 Win in Bladder Cancer; Gene Therapy Safety Overhang Fri, May 15, 2026
BeOne's Beqalzi Wins FDA Approval, Breaking BCL-2 Monopoly; Takeda Cuts 4,500 Jobs Thu, May 14, 2026
FDA Commissioner Makary Resigns; BMS-Hengrui $15.2B 13-Asset Alliance Wed, May 13, 2026
CSL Flags $5B Vifor Impairment as Shares Hit Nine-Year Low Tue, May 12, 2026
Vyvgart Wins Broadest gMG Label; Merck Closes $6.7B Terns Deal Mon, May 11, 2026
Trump Plans to Fire FDA Commissioner Makary; Leqembi SC Delayed to August Sat, May 9, 2026
Angelini's $4.1B Catalyst Buyout; Atara Surges 40% on FDA Path Forward; Roche Acquires PathAI Fri, May 8, 2026
Bayer Acquires Perfuse for $2.45B in Ophthalmology; Novo Wegovy Pill Posts $355M Q1 Thu, May 7, 2026
Cytokinetics Cracks Non-Obstructive HCM; Pfizer's $2.3B Trillium Write-Off Tue, May 5, 2026
SCOTUS Restores Mifepristone Mail Access; First PROTAC Drug Wins FDA Approval Tue, May 5, 2026
UCB's $2.2B Candid Therapeutics Deal; FDA Moves to Withdraw Tavneos Mon, May 4, 2026
FDA Approves First PROTAC Drug Veppanu; Pharma M&A Hits $84B in Q1; Truqap Clears ODAC 7-1 Mon, May 4, 2026
Erasca Crashes 48% on Patient Death; Lilly's $2.3B Ajax Deal Wed, Apr 29, 2026
Sun Pharma just wrote an eleven-point-seven-five billion dollar check to acquire Organon Tue, Apr 28, 2026
Foundayo Trails Oral Wegovy 5-to-1 in Week 2; Inhibrx Draws $6.7B Sat, Apr 25, 2026
Regeneron's Otarmeni Approved as First Gene Therapy for Hearing Loss Fri, Apr 24, 2026
Merck Welireg Fails First-Line Kidney Cancer; Lilly's $7B Kelonia CAR-T Wed, Apr 22, 2026
Lilly's $7B Kelonia In Vivo CAR-T Bet; TIGIT Fails Again at Gilead-Arcus Tue, Apr 21, 2026
Allogene's Off-the-Shelf CAR-T Clears Futility Bar; Kailera Prices $625M IPO Tue, Apr 21, 2026
Lilly Foundayo Clears Heart Safety for Diabetes Filing; Cochrane Calls Amyloid Drugs 'Trivial' Fri, Apr 17, 2026
J&J Q1 Earnings Beat on Tremfya Growth; Revolution Medicines $2B Raise Thu, Apr 16, 2026
Daraxonrasib Nearly Doubles Pancreatic Cancer Survival; Neurocrine-Soleno $2.9B Deal Tue, Apr 14, 2026
FDA Rejects Replimune RP1 Again; Sun Pharma's $12B Organon Bid; Amgen TEPEZZA Subcutaneous Win Mon, Apr 13, 2026
Lilly Launches Oral GLP-1 Foundayo; Gilead's $3.15B Tubulis ADC Acquisition Thu, Apr 9, 2026
Pharma Tariffs Hit 100% with Major Loopholes; Gilead's $3.15B Tubulis ADC Deal Wed, Apr 8, 2026
Gilead's $3.15B Tubulis ADC Deal; Neurocrine's $2.9B Prader-Willi Bet Wed, Apr 8, 2026
Lilly Foundayo vs Novo Oral Wegovy Launch War; Trump Signs 100% Pharma Tariff Mon, Apr 6, 2026
Trump's 100% Drug Tariffs Reshape Pharma; $25.5B M&A Spree Sat, Apr 4, 2026
Trump's 100% Drug Tariff Splits Pharma; Lilly Foundayo Approved Fri, Apr 3, 2026
FDA Approves Lilly's Foundayo Oral Obesity Pill; Immunovant Batoclimab Fails Phase 3 TED Trials Thu, Apr 2, 2026
Lilly's $7.8B Centessa Deal; Biogen Buys Apellis for $5.6B; FDA Flags Tavneos Deaths | Mar 31, 2026 Wed, Apr 1, 2026
Tyvaso's Second Phase 3 Win in IPF; Viridian Crashes 38% on TED Data Tue, Mar 31, 2026
Lilly's $2.75B AI Drug Deal with Insilico; Oral Psoriasis Data Reshapes Derm at AAD 2026 Mon, Mar 30, 2026
Novo Nordisk's Once-Weekly Insulin Awiqli Wins FDA Approval; $15B+ in Pharma Deals Sat, Mar 28, 2026
Wave Crashes 58% on Obesity Data Miss; CVC Bids $12.6B for Recordati Fri, Mar 27, 2026
Merck's $6.7B Terns Acquisition for CML Drug TERN-701 Thu, Mar 26, 2026
ImmunityBio's Third FDA Warning Letter; Gilead Bets $1.68B on Ouro Medicines Autoimmune Bispecifi... Wed, Mar 25, 2026
Apogee Eczema Data Sends Stock Up 20%; Gilead Nears $2B Ouro Medicines Deal Mon, Mar 23, 2026
Abbott's $21B Exact Sciences Deal Closes; Wegovy HD Approved, Orforglipron Delayed Mon, Mar 23, 2026
Novartis $2B Bet on PI3Kα in Breast Cancer; Opdivo Approved for Hodgkin Lymphoma Sat, Mar 21, 2026
Lilly Retatrutide Phase 3 Clears All Endpoints; FDA Approves Wegovy HD in 54 Days Fri, Mar 20, 2026
FDA Approves J&J's Oral Psoriasis Pill Icotyde; Bicycle Therapeutics Cuts 30% of Workforce Wed, Mar 18, 2026
Aldeyra's Third FDA Rejection Crashes Stock 68%; CytomX Masked ADC Surges 60% Wed, Mar 18, 2026
Structure Therapeutics Oral GLP-1 Data Rivals Orforglipron; BioMarin Halts Voxzogo Studies Tue, Mar 17, 2026
Immutep LAG-3 Phase 3 Failure Crashes Stock 88%; Ultragenyx Gene Therapy Hits OTc Mon, Mar 16, 2026
GSK Arexvy Expands to At-Risk Adults 18-49; Novartis Cosentyx Pediatric HS Approval Sat, Mar 14, 2026
Ultragenyx Gene Therapy Hits Phase 3 Endpoint; Lilly's $3B China Bet; LAG-3 Oncology Setback Fri, Mar 13, 2026
The AI Reckoning — Episode 4: Who Wins Thu, Mar 12, 2026
Vertex Kidney Drug Hits Phase 3; Lilly's $3B China Expansion; UCB Bimzelx Beats Skyrizi Thu, Mar 12, 2026
BioNTech's co-founders just walked away Wed, Mar 11, 2026
Novo Nordisk Partners with Hims on GLP-1 Distribution; BMS Wins Sotyktu PsA Approval Tue, Mar 10, 2026
The AI Reckoning — Episode 3: The Agentic Enterprise Mon, Mar 9, 2026
Weekend Round Up March 08, 2026: Gilead's $7.8B CAR-T Bet; Servier Acquires Day One for $2.5B Mon, Mar 9, 2026
FDA not convinced AMT-130 works; Moderna +14% on melanoma data; Servier’s $2.5B Day One bet Sat, Mar 7, 2026
Theravance Phase 3 CYPRESS Failure Triggers 50% Workforce Cut, Science CoRaises $230M for Retinal BCI + Sotyktu PsA PDUFA Tomorrow Fri, Mar 6, 2026
Moderna’s $2.25B LNP Patent Settlement, FDA Fires 30 GLP-1 Compounding Warning Letters + Sotyktu PsA PDUFA Friday Fri, Mar 6, 2026
AI Reckoning Ep 2: From Molecule to Market — 173 AI Drugs in Trials, But Phase 2 Data Tells a Different Story Thu, Mar 5, 2026
Novo’s $506M Oral GLP-1 Manufacturing Bet, Sotyktu PsA PDUFA Friday, Orforglipron Race Begins Tue, Mar 3, 2026
Gilead’s $7.8B CAR-T Bet, YUVIWEL Approved, PADCEV-Keytruda Resets Bladder Cancer Tue, Mar 3, 2026
CagriSema Week of Reckoning: Analysts Revise, Novo Regroups | YUVIWEL Approved + PRV Voucher | Weekend Edition Tue, Mar 3, 2026
CagriSema's New Story After REDEFINE 4, GSK's $950M Activin Bet, Lilly Wins ACHIEVE-3 Tue, Mar 3, 2026
AI Reckoning Ep 1: The Reckoning — 5% of Pharma Has AI Advantage, 95% Still Running Pilots Mon, Mar 2, 2026